BIOTRONIK built Germany's first pacemaker in 1963 and retains development and production centers in Germany, the US, and Singapore. Its Micro Systems Technologies unit provides a vertically integrated implant supply chain few rivals replicate.

Home Monitoring remote patient management is supported by randomized evidence (IN-TIME mortality benefit), and the company cites 100,000 implanted DX devices. 2026 regulatory firsts include FDA approval of Solia CSP S (first pacing lead designed specifically for LBBAP) and first-in-human LivIQ implants (first leadless pacemaker with AV-synchronous pacing via atrial far-field sensing).

Public records include a ~$4.9M US kickback settlement (2014), a $12.95M False Claims Act settlement over alleged improper payments to physicians from 2013-2021 (2022), a Dutch investigation reported since 2020, and a 2016 New Mexico negligence verdict with punitive damages.

As a privately held SE & Co. KG, BIOTRONIK publishes no revenue figures, unlike listed peers Medtronic, Abbott, and Boston Scientific. The Teleflex divestiture removed its stent, drug-coated balloon, and covered-stent lines, concentrating revenue in CRM and neuromodulation where larger competitors hold greater scale.

The company explicitly names aging populations, shrinking care budgets, and resource limits as demand drivers. Its pipeline targets growth segments: conduction system pacing (FDA-approved Solia CSP S for LBBAP), leadless pacing with AV synchrony (global BIO-LivIQ pivotal trial), and non-opioid chronic pain therapy via Prospera SCS.

2025-2026 partnerships (Charite/Deutsches Herzzentrum, MiCare Path RPM, University of Sydney through 2028) extend its connected-care bet against large-cap CRM/neuromodulation incumbents.

The 2025-02-27 announcement, quoting then-CEO Dr. Alexander Uhl, committed investment to CRM, Patient Monitoring, Heart Failure, and Neuromodulation around AI and connected care; Teleflex completed the VI acquisition in mid-2025.

The legal entity is BIOTRONIK SE & Co KG with managing directors Holger Krumel-van Randenborgh (chairman), Andreas Hecker, and Arne Kolfenbach, reflecting a leadership transition from Uhl since the announcement. The company reports more than 9,000 employees across over 100 countries, entered neuromodulation via the 2023 Prospera FDA approval, and holds a 2026 cadence of FDA approvals, LivIQ first-in-human implants, and BIOTRONIK Neuro Embrace One AI.

No price or fee information appears on the official site, consistent with a business-to-business device model procured through hospital tenders and public/private reimbursement following FDA/CE approval.

Value communication emphasizes evidence and workflow economics rather than rates - e.g., C-SIGN registry data suggesting Solia CSP S saves ~15 minutes per CSP procedure, and claims that automatic daily remote monitoring reduces clinic burden.

The CRM portfolio spans pacing systems, ICDs and leads, CRT systems, implantable cardiac monitors, remote patient monitoring, programmers, and lead delivery systems; neuromodulation centers on the Prospera Spinal Cord Stimulation system for chronic intractable pain; electrophysiology covers arrhythmia diagnosis and treatment.

Micro Systems Technologies supplies the active implant industry in-house with ceramic substrates, substrate assembly, semiconductor packaging, primary batteries, and feedthroughs. The February 2025 divestiture of the Vascular Intervention business (Orsiro stent, PK Papyrus, Freesolve scaffold) to Teleflex, completed in 2025, narrowed the portfolio toward active implants and digital health.